stockrow
Monday 9 November 2026
Export ALMR’s income statement to Excel — free account
Alamar Biosciences, Inc.
ALMRAlamar Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.2 million, up 195.2% from fiscal 2024.
- Revenue
- +68.5%
- EPS
- +72.0%
- Free cash flow
- +1.07%
Quarter to September 2026, against a year earlier
28.05
1.14
+4.24%
Follow ALMR
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+4 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.09 | 3.09 | 15.83 | 20.64 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(13.26) | (13.26) | (140.37) | (159.82) | |
P/B ratio |
0.00 | 0.00 | 5.08 | 7.75 | |
Price to Tangible BV |
0.00 | 0.00 | 5.11 | 7.79 | |
EV/Sales |
3.21 | 3.21 | 13.43 | 18.74 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.60) | (4.60) | (22.36) | (35.09) | |
EV/FCF |
(4.22) | (4.22) | (19.66) | (31.22) | |
Quick Ratio |
1.80 | 3.50 | 9.67 | 7.41 | |
Current Ratio |
3.99 | 5.88 | 11.85 | 9.49 | |
Net Debt/EBITDA |
3.47 | (0.93) | 19.26 | 16.10 | |
Debt/Assets |
7.01% | 40.21% | 2.54% | 0.00% | |
Debt/Equity |
(0.06) | (0.42) | 0.03 | 0.00 | |
Asset Turnover |
0.00 | 0.52 | 0.51 | 0.43 | |
Operating CF/Net income |
2.03 | 0.95 | 0.86 | 1.10 | |
Capex/Depreciation |
(2.44) | (0.49) | (3.41) | (0.43) | |
Interest Coverage |
(31.43) | (55.37) | (60.41) | (98.95) | |
Research and Development Expense of Revenue |
40.20% | 50.00% | 46.95% | 48.19% | |
Selling, General and Administrative Expense of Revenue |
46.90% | 52.96% | 59.24% | 58.48% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 5.63% | 11.15% | 11.67% | |
Graham Net Nets |
(0.83) | (0.83) | 0.16 | 0.10 | |
Graham Number |
28.28 | 34.50 | 0.00 | 0.00 | |
Earnings Yield |
(16.55%) | (16.55%) | (11.98%) | (8.07%) | |
Free Cash Flow Yield |
(24.58%) | (24.58%) | (4.32%) | (2.91%) | |
Revenue per Share |
2.17 | 2.12 | 0.50 | 0.49 | |
Operating CF per Share |
(1.26) | (1.66) | (0.19) | (0.21) | |
Capex per Share |
(0.25) | (0.05) | (0.06) | (0.01) | |
Free Cash Flow per Share |
(1.50) | (1.71) | (0.26) | (0.22) | |
Cash per Share |
2.60 | 5.27 | 4.26 | 3.28 | |
Shareholders Equity per Share |
(13.76) | (14.52) | 5.33 | 4.39 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(13.76) | (14.52) | 5.33 | 4.39 | |
Free Cash Flow |
(17.36) | (20.95) | (14.96) | (15.19) | |
Working Capital |
70.98 | 117.43 | 303.42 | 284.21 | |
Capital Expenditures |
(2.84) | (0.60) | (3.64) | (0.46) | |
Net Current Asset Value |
(204.24) | (223.05) | 253.26 | 243.37 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.11 | 0.02 | 0.12 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | — | 14.13 | |
Average Payables |
— | — | — | 11.37 | |
Average Inventory |
— | — | — | 34.27 | |
Average Assets |
— | 167.98 | 195.49 | 263.77 | |
Average Common Equity |
— | — | — | 85.15 |
Columns are period end dates · fundamentals updated 6 Nov 2026